marijuana stock news

TransCanna December Revenues Increases 20% from November

 TransCanna Holdings Inc. (CSE: TCAN) (FSE: TH8) (“TransCanna” or the “Company”) is pleased to announce that the company has increased its revenues from November by 20% to CAD $564,000.00. The net income from operations was CAD $91,000 which is slightly over 16%. The company had recurring revenue in flower, a significant increase in Soldaze edibles with the majority of the increase coming from the continued growth in the manufacturing and distribution units of the company.

“It is very encouraging to see significant growth in our edibles, manufacturing and distribution business units” said Steve Giblin president and CEO of TransCanna. “In addition to the ongoing sales of flower from Lyfted Farms, our Soldaze edibles attracted consumer attention after winning multiple awards at the Emerald Cup. Our plan is to grow all four business units simultaneously so we have steady and balanced revenue growth moving forward.”

In additional news the company opened the last room in the expansion of our Lyfted Farms facilites. With the completion of the construction focus will turn to maximizing the yield from the expanded space.

This will be the last monthly revenue target announced as for 2020 the plan will be to shift to standard Quarterly reporting.

About TransCanna Holdings Inc.

TransCanna Holdings Inc. is a California based, Canadian listed, company building Cannabis-focused brands for the California lifestyle, through its wholly-owned California subsidiaries.

For further information, please visit the Company’s website at www.transcanna.com or email the Company at info@transcanna.com.

On behalf of the Board of Directors
Steve Giblin
President
604-609-6199

The information in this news release includes certain information and statements about management’s view of future events, expectations, plans, and prospects that constitute forward-looking statements. These statements are based upon assumptions that are subject to significant risks and uncertainties. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance may differ materially from those anticipated and indicated by these forward-looking statements. Forward-looking statements in this news release include, but are not limited to: timing of the completion of the SPA and the satisfaction of closing conditions, and the expected benefits of Lyfted to the Company’s business. Any number of factors could cause actual results to differ materially from these forward-looking statements as well as future results. Although the Company believes that the expectations reflected in forward-looking statements are reasonable, it can give no assurances that the expectations of any forward-looking statements will prove to be correct. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking statements or otherwise.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

1933 Industries Inc. (TGIFF) (TGIF) Signs Licensing Agreement with Established Premium Cannabis Company

1933 Industries Signs Licensing Agreement with Established Premium Cannabis Company The Bloom…

$TURV Development Commences Operations

GrowCo Business Development Commences Operations Providing Grower Services to First Tenant DENVER,…

$PMCB Improved Technology Attracting World Class Oncologists

PharmaCyte Biotech’s Improved Technology Attracting World Class Oncologists PharmaCyte Biotech (PMCB) is…